Boulder-based lung cancer diagnostic company Biodesix recently received a patent for its proprietary blood specimen collection device.
The new device enhances ease of use, and reduces cost and environmental impact of the collection, processing and shipping of samples, according to a company news release.
The device currently used “with the Biodesix Nodify XL2 test, replaces the need for processing samples used for proteomic testing on-site and shipping blood tubes, which often requires cold-chain logistics during transit to the testing laboratory,” the release states.
Biodesix plans to make the device available for purchase by labs and diagnostic companies looking to use the new technology for sample processing and testing.
Source link